TuHURA Biosciences, Inc. (HURA)

TuHURA Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	3.35	4.14	2.01
Research & Development	11.27	9.4	7.93
Operating Expenses	14.61	13.55	9.93
Operating Income	-14.61	-13.55	-9.93
Interest Expense	-3.63	-0.02	-
Interest & Investment Income	0.21	0.09	0.06
Other Non Operating Income (Expenses)	-0.31	0.04	0.21
EBT Excluding Unusual Items	-18.35	-13.43	-9.66
Other Unusual Items	-	0.33	0.29
Pretax Income	-18.37	-29.32	-9.37
Net Income	-18.37	-29.32	-9.37
Net Income to Common	-19.33	-29.32	-9.37
Shares Outstanding (Basic)	76	68	-
Shares Outstanding (Diluted)	76	68	-
EPS (Basic)	-0.25	-0.43	-
EPS (Diluted)	-0.25	-0.43	-
Free Cash Flow	-15.24	-13.25	-7.54
Free Cash Flow Per Share	-0.20	-0.20	-
EBITDA	-14.48	-13.37	-9.56
D&A For EBITDA	0.14	0.18	0.37
EBIT	-14.61	-13.55	-9.93

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q